Kampo formula hochu-ekki-to (Bu-Zhong-Yi-Qi-Tang, TJ-41) ameliorates muscle atrophy by modulating atrogenes and AMPK in vivo and in vitro.

Mitsutaka YakabeTatsuya HosoiHiroko SasakawaMasahiro AkishitaSumito Ogawa

Published in: BMC complementary medicine and therapies (2022)

TJ-41 inhibited atrogenes in an Akt-independent manner as well as activating AMPK in skeletal muscles in vivo, further implying the therapeutic potential of TJ-41 against disuse-induced muscle atrophy and other atrogenes-dependent atrophic conditions.

Keyphrases

skeletal muscle
signaling pathway
high glucose
diabetic rats
cell proliferation
protein kinase
mouse model
human milk
drug induced
endothelial cells
preterm infants